Implementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 2: Train-the-Trainer
Study Details
Study Description
Brief Summary
The train-the-trainer (TTT) approach is a promising method of sustaining training efforts in community mental health centers (CMHCs). This study will test the implementation and effectiveness outcomes of a sleep treatment delivered by CMHC providers who are trained and supervised within CMHCs via TTT. The investigators will test two versions of the sleep treatment, a "Standard" version and an "Adapted" version that has been adapted using theory, data and stakeholder inputs to improve the fit for SMI patients treated in community mental health centers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
There are significant barriers to widespread implementation and sustainment of evidence-based psychological treatments (EBPTs) in community mental health centers (CMHCs), including insufficient time and funding, shortage of trainers and consultants, and staff turnover. The investigators propose to evaluate one possible solution, the train-the-trainer (TTT) approach, in the context of a transdiagnostic EBPT for sleep and circadian dysfunction-the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)- for serious mental illness (SMI) in CMHCs. This entry describes the Train-the-Trainer Phase, the second of a three-phase hybrid type 2 effectiveness-implementation trial conducted to test TranS-C in CMHCs.
TTT is a training structure with multiple levels, called "Generations." First, external expert trainers train an initial cohort of providers in a specific EBPT ("Generation 1 providers"). Next, Generation 1 providers are offered additional training in how to train others in the EBPT and become "local trainers." These local trainers then train the next cohort of providers within their organization ("Generation 2 providers").
The Train-the-Trainer Phase builds upon the first phase, the Implementation Phase (NCT04154631), in which implementation and effectiveness outcomes of two versions of TranS-C, Standard and Adapted are compared, with CMHC providers, who are trained by treatment experts. Adapted TranS-C is a version of TranS-C designed to improve 'fit' with the CMHC context. In the Train-the-Trainer Phase, the aim is to test implementation and effectiveness outcomes of Standard and Adapted TranS-C with CMHC providers who are trained and supervised within CMHCs (i.e., Generation 2 of TTT).
In the Implementation Phase, 10 CMHC clinic sites were cluster randomized to either Standard or Adapted TranS-C. Nine CMHCs continued participation into the Train-the-Trainer Phase. Within each CMHC site, patients are randomized to immediate TranS-C or to Usual Care followed by Delayed Treatment (UC-DT). Generation 2 patients (n=130) will be assessed pre, mid and post-treatment and at 6 month follow-up. UC Berkeley will coordinate the research, facilitate implementation, collect data, etc. Generation 2 providers (n=60), trained by local trainers within an established network of CMHCs, will implement TranS-C and will be assessed at pre and post-treatment. SA1 is to confirm that both Standard vs. Adapted TranS-C, compared to UC-DT, improve sleep and circadian functioning and reduce functional impairment and disorder-focused psychiatric symptoms for Generation 2 patients. SA2 is to evaluate the fit, to the CMHC context, of Standard vs. Adapted TranS-C via Generation 2 provider ratings of acceptability, appropriateness and feasibility. SA3 will examine if better fit, operationalized via Generation 2 provider ratings of acceptability, mediates the relationship between treatment condition and Generation 2 patient outcome. This research will determine if (1) sleep and circadian problems can be effectively addressed in SMI by CMHC providers trained and supervised within CMHCs via the train-the-trainer approach, (2) test two variations of TranS-C that each have unique advantages and focus on community providers and typical community patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Standard TranS-C Standard TranS-C is modularized and delivered across eight 50-minute, weekly, individual sessions. It is comprised of 4 cross-cutting interventions featured in every session; 4 core modules that apply to the vast majority of patients; and 7 optional modules used less commonly, depending on the presentation. |
Behavioral: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
|
| Experimental: Adapted TranS-C The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions. |
Behavioral: Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
|
| Active Comparator: UC-DT Usual Care Delayed Treatment. Usual care in the partner CMHCs starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring). |
Other: Usual Care Delayed Treatment
Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
|
Outcome Measures
Primary Outcome Measures
- Patient-level outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment, to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses perceived functional impairments related to sleep problems using a self-report questionnaire. The minimum value is 8. The maximum value is 40. Higher scores mean more sleep disturbance (worse outcome).
- Provider-level outcome: Acceptability Intervention Measure [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment for each client, and to post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Assesses provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire and provider feedback.
Secondary Outcome Measures
- Patient-level outcome: Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment, to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses perceived functional impairments related to sleep problems in a self-report questionnaire. The minimum value is 16. The maximum value is 80. Higher scores mean more sleep related problems (worse outcome).
- Patient-level outcome: Composite Sleep Health Score [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment, to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Composite Sleep Health Score which is defined as the sum of scores on 6 sleep health dimensions: Regularity (Midpoint fluctuation), Satisfaction (Sleep quality question on PROMIS-SD), Alertness (Daytime sleepiness question on PROMIS-SRI), Timing (Mean midpoint), Efficiency (Sleep efficiency) and Duration (Total Sleep Time).
- Patient-level outcome: Midpoint of Sleep Measure [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment, to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses circadian functioning by calculating the midpoint between falling asleep time and rise time.
- Patient-level outcome: Sheehan Disability Scale [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses functional impairment on a scale from 0 to 30, where higher scores mean higher impairment.
- Patient-level outcome: The Diagnostic and Statistical Manual of Mental Disorders Cross-Cutting Symptom Measure [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses disorder-focused psychiatric symptoms using a self-report questionnaire. Each item on the measure is rated on a 5-point scale (from 0-4), where higher scores indicate a higher frequency of psychiatric symptoms (worse outcome).
- Provider-level outcome: Intervention Appropriateness Measure [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment for each client, and to post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Assesses provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire
- Provider-level outcome: Feasibility of Intervention Measure [Change from baseline, to mid-treatment, which is 2 or 4 weeks after the beginning of treatment for each client, and to post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Assesses provider perceptions of the feasibility of the intervention using a self-report questionnaire.
Other Outcome Measures
- Patient-level outcome: Alcohol Intake [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses past 30-day quantity and frequency of alcohol intake using a self-report questionnaire.
- Patient-level outcome: Substances Intake [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses past 30-day frequency of substance use using a self-report questionnaire.
- Patient-level outcome: Tobacco Intake [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses past 30-day quantity and frequency of tobacco intake using a self-report questionnaire.
- Patient-level outcome: Caffeine Intake [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses past 30-day quantity and frequency of caffeine intake using a self-report questionnaire.
- Patient-level outcome: Suicidal Ideation Questionnaire [Change from baseline to post-treatment, which is 6 or 10 weeks after the beginning of treatment, and to 6-month follow-up.]
Assesses past 30-day suicidal ideation using a self-report questionnaire.
- Patient-level outcome: Credibility Expectancy Questionnaire [Once at post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Measures the credibility and expectation of improvement from TranS-C. The questionnaire includes 4 items.
- Patient-level outcome: Utilization Questionnaire [Once at post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Measures the elements of TranS-C that are most used.
- Patient-level outcome: Utilization Questionnaire [Once at 6-month follow-up after treatment ends.]
Measures the elements of TranS-C that are most used.
- Patient-level outcome: Duke Checklist of Medical Conditions & Symptoms [Once at baseline.]
Assesses physical illness or neurological degenerative disease directly related to the onset and course of the sleep and circadian dysfunction.
- Provider-level outcome: Checklist of Modules Delivered [Once at each session between patient and provider.]
Assesses which treatment modules were delivered by the providers using a self-report checklist.
- Provider-level outcome: Adaptations to Evidence-Based Practices Scale [Once at post-treatment, which is 6 or 10 weeks after the beginning of treatment.]
Assesses ad hoc modifications the provider made to the treatment using a self-report questionnaire.
- Provider-level outcome: Use of TranS-C Assessment [Once during the 1 year sustainment phase.]
Assesses if providers continue to use TranS-C in a self-report questionnaire.
- Provider-level outcome: Session attendance and duration log [Once at each session between patient and provider.]
Collect session date and duration (length of session).
- Provider-level outcome: Training evaluation/knowledge test [Through the first 2.5 years of the study, an average of 4 per month]
Provider evaluation of the training; provider knowledge of content covered in the training; provider willingness and confidence in delivering TranS-C.
- Provider-level outcome: Gold Standard Training Elements [Through the first 2.5 years of the study, an average of 4 per month]
Extent of gold standard training elements present in each training session, with respect to content and technique.
- Provider-level outcome: Number of TranS-C Sessions [Once per patient at posttreatment, which is 6 or 10 weeks after the beginning of treatment]
Number of sessions delivered to each enrolled patient by each provider.
- Facilitator-level outcome: Implementation Log [Up to 30 months]
Weekly record of facilitator activities, amount of time per activity, county, year, type of communication, implementation strategies, target(s), intended outcome(s).
- Facilitator-level outcome: Meeting Log [Up to 30 months]
Weekly record of community meeting details as applicable, including: county, generation, level of contact (i.e., leadership, providers), type/modality of contact, length of meeting, number of attendees, recording, general description, standardized description, main presenter and role of UC Berkeley staff.
Eligibility Criteria
Criteria
Inclusion Criteria:
The inclusion criteria for the CMHC local trainers are:
-
Employed in participating CMHCs
-
Completed a Generation 1 TranS-C training (i.e., led by UC Berkeley expert trainers)
-
Volunteer to participate and formally consent to participate
The inclusion criteria for CMHCs are:
-
Publicly funded adult mental health outpatient services
-
Support from CMHC leadership
The inclusion criteria for CMHC providers are:
-
Employed or able to deliver client-facing services to CMHC clients
-
Interest in learning and delivering TranS-C
-
Volunteer to participate and formally consent to participate
Consumers must meet the following inclusion criteria:
-
Aged 18 years and older
-
Meet criteria for an SMI per self-report and confirmed by referring provider or administration of the Mini International Neuropsychiatric Interview (MINI) (DSM-5, Version 7.0.0) by a licensed clinical social worker on the research team
-
Exhibit a sleep or circadian disturbance as determined by endorsing 4 "quite a bit" or 5 "very much" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions
-
Receiving the standard of care for the SMI and consent to regular communications between the research team and provider
-
Consent to access their medical record and participate in assessments
-
Guaranteed place to sleep for at least 2 months that is not a shelter
Exclusion Criteria:
-
Presence of an active and progressive physical illness or neurological degenerative disease directly related to the onset and course of the sleep and circadian dysfunction, or making participation in the study unfeasible based on confirmation from the treating clinician and/or medical record
-
Presence of substance abuse/dependence only if it makes participation in the study unfeasible
-
Current active intent or plan to commit suicide (those with suicidal ideation are eligible) only if it makes participation in the study unfeasible, or homicide risk
-
Night shift work >2 nights per week in the past 3 months
-
Pregnancy or breast-feeding
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Contra Costa Health, Housing, and Homeless Services Division | Concord | California | United States | 94520 |
| 2 | Solano County Department of Health & Social Services, Behavioral Health Services | Fairfield | California | United States | 94533 |
| 3 | Kings County Behavioral Health | Hanford | California | United States | 93230 |
| 4 | Lake County Behavioral Health Services | Lucerne | California | United States | 95458 |
| 5 | Alameda County Behavioral Health Care Services | Oakland | California | United States | 94606 |
| 6 | Placer County Health and Human Services, Adult System of Care | Roseville | California | United States | 95678 |
| 7 | Monterey County Behavioral Health | Salinas | California | United States | 93906 |
| 8 | Bay Area Community Health | San Jose | California | United States | 95148 |
| 9 | County of Santa Cruz Behavioral Health Services for Children and Adults | Santa Cruz | California | United States | 95060 |
Sponsors and Collaborators
- University of California, Berkeley
Investigators
- Principal Investigator: Allison Harvey, PhD, University of California, Berkeley
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- R01MH120147_P2
- R01MH120147